- Clinical Trials
- April 2024
- 50 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2025
- 62 Pages
Global
From €3336EUR$3,495USD£2,795GBP
- Report
- January 2022
- 200 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- August 2022
Global
From €754EUR$790USD£632GBP
- Report
- November 2022
- 85 Pages
Global
From €1909EUR$2,000USD£1,599GBP
Supranuclear Palsy (SP) is a rare neurological disorder that affects movement, balance, and eye movements. It is caused by the degeneration of certain areas of the brain, leading to a range of symptoms including difficulty walking, speaking, and swallowing. Treatment for SP is largely supportive, with medications used to manage symptoms such as muscle spasms, depression, and anxiety.
The Supranuclear Palsy Drug market is a subset of the Central Nervous System Drugs market, which includes medications used to treat neurological disorders. These drugs are typically prescribed by neurologists and psychiatrists, and are used to manage symptoms such as muscle spasms, depression, and anxiety. The market is highly competitive, with a range of generic and branded medications available.
Some companies in the Supranuclear Palsy Drug market include Pfizer, Novartis, Merck, and GlaxoSmithKline. Show Less Read more